Myeloid Metaplasia – Pipeline Review, H2 2011 by GlobalMarketsDirect

VIEWS: 3 PAGES: 38

More Info
									Myeloid Metaplasia – Pipeline Review, H2 2011




             Myeloid Metaplasia – Pipeline Review, H2 2011


                                                                                          Reference Code: GMDHC1611IDB
                                                                                          Publication Date: December 2011




Myeloid Metaplasia – Pipeline Review, H2 2011                                             GMDHC1611IDB / Pub December 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                            Page(1)
Myeloid Metaplasia – Pipeline Review, H2 2011




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 4
    List of Figures ................................................................................................................................................................................ 4
Introduction......................................................................................................................................................................................... 5
    Global Markets Direct Report Coverage ........................................................................................................................................ 5
Myeloid Metaplasia Overview ............................................................................................................................................................. 6
Therapeutics Development................................................................................................................................................................. 7
    An Overview of Pipeline Products for Myeloid Metaplasia............................................................................................................. 7
Myeloid Metaplasia Therapeutics under Development by Companies ............................................................................................... 9
Myeloid Metaplasia Therapeutics under Investigation by Universities/Institutes .............................................................................. 10
Mid Clinical Stage Products.............................................................................................................................................................. 11
    Comparative Analysis .................................................................................................................................................................. 11
Myeloid Metaplasia Therapeutics – Products under Development by Companies ........................................................................... 12
Myeloid Metaplasia Therapeutics – Products under Investigation by Universities/Institutes ............................................................ 13
Companies Involved in Myeloid Metaplasia Therapeutics Development .......................................................................................... 14
    Novartis AG ................................................................................................................................................................................. 14
    Celgene Corporation ................................................................................................................................................................... 15
Myeloid Metaplasia – Therapeutics Assessment.............................................................................................................................. 16
    Assessment by Monotherapy Products ....................................................................................................................................... 16
    Assessment by Combination Products ........................................................................................................................................ 17
    Assessment by Route of Administration ...................................................................................................................................... 18
    Assessment by Molecule Type .................................................................................................................................................... 20
Drug Profiles..................................................................................................................................................................................... 22
    Afinitor - Drug Profile ................................................................................................................................................................... 22
         Product Description................................................................................................................................................................. 22
         Mechanism of Action ............................................................................................................................................................... 22
         R&D Progress ......................................................................................................................................................................... 22
    BMS-354825 - Drug Profile.......................................................................................................................................................... 24
         Product Description................................................................................................................................................................. 24
         Mechanism of Action ............................................................................................................................................................... 24
         R&D Progress ......................................................................................................................................................................... 24
    R115777 - Drug Profile ................................................................................................................................................................ 26
         Product Description................................................................................................................................................................. 26
         Mechanism of Action ............................................................................................................................................................... 26
         R&D Progress ......................................................................................................................................................................... 26
    Actimid + Prednisone - Drug Profile ............................................................................................................................................ 27
         Product Description................................................................................................................................................................. 27
         Mechanism of Action ............................................................................................................................................................... 27
         R&D Progress ......................................................................................................................................................................... 27
    Thalidomide - Drug Profile ........................................................................................................................................................... 28
         Product Description................................................................................................................................................................. 28
         Mechanism of Action ............................................................................................................................................................... 28



Myeloid Metaplasia – Pipeline Review, H2 2011                                                                                             GMDHC1611IDB / Pub December 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                   Page(2)
Myeloid Metaplasia – Pipeline Review, H2 2011



         R&D Progress ......................................................................................................................................................................... 28
    Pegasys - Drug Profile ................................................................................................................................................................. 29
         Product Description................................................................................................................................................................. 29
         Mechanism of Action ............................................................................................................................................................... 29
         R&D Progress ......................................................................................................................................................................... 29
    Zometa - Drug Profile .................................................................................................................................................................. 30
         Product Description................................................................................................................................................................. 30
         Mechanism of Action ............................................................................................................................................................... 30
         R&D Progress ......................................................................................................................................................................... 30
    Gleevec - Drug Profile ......................................................................
								
To top